Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today provides key insights from its June 10 webinar, "Inside MEAI," during which the Company’s CEO and the leading investigators of the Company’s ongoing first-in-human clinical trial of CMND-100 (the "Trial"), provided an update based on their "hands-on" experience from the  Trial.

Based on the data available to date from the Trial, Dr. Anahita Bassir Nia of Yale School of Medicine and Dr. Jennifer Ellis of Johns Hopkins University have conveyed a generally positive impression of CMND‑100 and the ongoing Phase I/IIa study.  They highlighted the significant unmet need in Alcohol Use Disorder (AUD), where currently available treatments are limited in number and often accompanied by notable side effects.

 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.